Omentin 1 (human), ELISA kit



APO-54N-034-KI01	96 wells	819.00 USD

Please mouse over

Product Specification

Alternative Name:	Intelectin-1, Intestinal Lactoferrin receptor, Galactofuranose-binding lectin, Endothelial lectin HL-1

Sensitivity:	0.4ng/ml (range 0.5 to 32ng/ml).

Application:	For the quantitative determination of human omentin 1 (intelectin-1) from biological fluids (serum, plasma and cell culture supernatant).

Short Term Storage:	+4°C

Long Term Storage:	-20°C

Handling:	Avoid freeze/thaw cycles.

Miscellaneous/General:	Obesity is strongly associated to the insulin resistance syndrome, which includes type 2 diabetes mellitus, and to an increased risk of atherosclerotic cardiovascular disease [1]. Several studies have reported that visceral obesity (fat located within omental and mesenteric fat depots) is more closely associated with insulin resitance, type 2 diabetes and cardiovascular disease than is peripheral obesity (subcutaneous) [2]. Omentin 1 (also named Omentin, Intelectin-1, Endothelial Lectin HL-1 and Intestinal Lactoferrin Receptor) has been identified as a major visceral (omental) fat secretory adipokine [3]. Omentin 1 is a secreted protein of ~38kDa containing a fibrinogen-related domain that is highly expressed in the omental fat, and much less in intestine, lung and heart. Addition of recombinant Omentin 1 in vitro does not affect basal, but enhances insulin-stimulated glucose uptake in subcutaneous as well as in omental human adipocytes. Omentin 1 triggers AKT signalling in the absence of insulin [3]. Omentin 1 plasma levels measured by western blotting are decreased in obesity [4]. Omentin 1 is decreased in patients with polycystic ovary syndrome (PCOS), a disease associated with insulin resistance and obesity [5]. Glucose and Insulin negatively regulate Omentin-1 levels ex vivo and in vivo [5].

Background / Technical Information:	UniProt ID Q8WWA0: Intelectin-1 (human) [Precursor]

Product Literature References

Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose: B.K. Tan, et al.; Diabetes 57, 801 (2008), Abstract; Full Text

General Literature References

Omentin-1, a novel adipokine, is decreased in overweight insulin resistant women with the polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose: B.K. Tan, et al.; Diabetes 57, 801 (2008), Abstract;

Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose: B.K. Tan, et al.; Diabetes 57, 801 (2008), Abstract;

Omentin plasma levels and gene expression are decreased in obesity: C.M. de Souza Batista, et al.; Diabetes 56, 1655 (2007), Abstract;

Abdominal obesity and metabolic syndrome: J.P. Després & I. Lemieux; Nature 444, 881 (2006), Abstract;

Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action: R.Z. Yang, et al.; Am. J. Physiol. Endocrinol. Metab. 290, E1253 (2006), Abstract;

Obesity wars: molecular progress confronts an expanding epidemic: J.S. Flier; Cell 116, 337 (2004), Abstract;